What is HC Wainwright’s Estimate for XBIO FY2025 Earnings?

Xenetic Biosciences Inc (NASDAQ:XBIO) – HC Wainwright reduced their FY2025 earnings estimates for shares of Xenetic Biosciences in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($3.24) for the year, down from their previous forecast of ($0.66). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2026 earnings at ($0.45) EPS, FY2027 earnings at ($0.54) EPS and FY2028 earnings at ($0.48) EPS.

Xenetic Biosciences Stock Up 2.0 %

XBIO stock opened at $3.44 on Monday. The business’s 50-day moving average price is $3.96 and its 200-day moving average price is $3.99. The stock has a market cap of $5.30 million, a P/E ratio of -1.29 and a beta of 2.17. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Tuesday, March 18th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.48). The company had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $0.18 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation acquired a new position in Xenetic Biosciences Inc (NASDAQ:XBIO) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned approximately 0.71% of Xenetic Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.